174 related articles for article (PubMed ID: 35428668)
1. Dental management of a patient with systemic mastocytosis.
Legge AR; Whyte A; Heywood S
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35428668
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
[TBL] [Abstract][Full Text] [Related]
3. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients.
Doyle LA; Sepehr GJ; Hamilton MJ; Akin C; Castells MC; Hornick JL
Am J Surg Pathol; 2014 Jun; 38(6):832-43. PubMed ID: 24618605
[TBL] [Abstract][Full Text] [Related]
4. A case report on concurrent occurrence of systemic mastocytosis and myeloid sarcoma presenting with extensive skin involvements and the results of genetic study.
Wang X; Zhang L; Zhou D; Cai H; Wang X; Jiang X
Medicine (Baltimore); 2020 Dec; 99(50):e21948. PubMed ID: 33327223
[TBL] [Abstract][Full Text] [Related]
5. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
6. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
[TBL] [Abstract][Full Text] [Related]
7. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
[TBL] [Abstract][Full Text] [Related]
8. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.
Álvarez-Twose I; Jara-Acevedo M; Morgado JM; García-Montero A; Sánchez-Muñoz L; Teodósio C; Matito A; Mayado A; Caldas C; Mollejo M; Orfao A; Escribano L
J Allergy Clin Immunol; 2016 Jan; 137(1):168-178.e1. PubMed ID: 26100086
[TBL] [Abstract][Full Text] [Related]
9. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage).
Pardanani A
Blood; 2013 Apr; 121(16):3085-94. PubMed ID: 23426950
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
[TBL] [Abstract][Full Text] [Related]
11. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
12. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
13. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
[TBL] [Abstract][Full Text] [Related]
14. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
Schneeweiss M; Peter B; Bibi S; Eisenwort G; Smiljkovic D; Blatt K; Jawhar M; Berger D; Stefanzl G; Herndlhofer S; Greiner G; Hoermann G; Hadzijusufovic E; Gleixner KV; Bettelheim P; Geissler K; Sperr WR; Reiter A; Arock M; Valent P
Haematologica; 2018 May; 103(5):799-809. PubMed ID: 29439183
[TBL] [Abstract][Full Text] [Related]
15. Mastocytosis: oral implications of a rare disease.
Rama TA; Côrte-Real I; Gomes PS; Escribano L; Fernandes MH
J Oral Pathol Med; 2011 Jul; 40(6):441-50. PubMed ID: 21198873
[TBL] [Abstract][Full Text] [Related]
16. New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy.
Valent P; Akin C; Sperr WR; Horny HP; Arock M; Metcalfe DD; Galli SJ
Annu Rev Pathol; 2023 Jan; 18():361-386. PubMed ID: 36270293
[TBL] [Abstract][Full Text] [Related]
17. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice.
Valent P; Hartmann K; Schwaab J; Alvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Carter MC; Hoermann G; Sperr WR; Butterfield JH; Ustun C; Zanotti R; Radia DH; Castells M; Triggiani M; Schwartz LB; Orfao A; George TI; Sotlar K; Gotlib J; Reiter A; Horny HP; Arock M; Akin C; Metcalfe DD
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1999-2012.e6. PubMed ID: 35342031
[TBL] [Abstract][Full Text] [Related]
18. Mastocytosis: from a Molecular Point of View.
Komi DEA; Rambasek T; Wöhrl S
Clin Rev Allergy Immunol; 2018 Jun; 54(3):397-411. PubMed ID: 28725969
[TBL] [Abstract][Full Text] [Related]
19. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
20. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Shomali W; Gotlib J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]